<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916123</url>
  </required_header>
  <id_info>
    <org_study_id>0812010139</org_study_id>
    <nct_id>NCT00916123</nct_id>
  </id_info>
  <brief_title>Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer</brief_title>
  <official_title>A Phase I Trial of Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Anti-prostate-specific Membrane Antigen Monoclonal Antibody in Patients With Metastatic, Castrate-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591
      antibody in combination with docetaxel chemotherapy against metastatic, castrate-resistant
      prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done because the standard treatments for metastatic prostate cancer
      that is growing despite medical or surgical therapies are not curative. Existing treatments,
      such as the docetaxel used as part of this study, may work temporarily, but unfortunately the
      cancer continues to grow. This test drug, 177Lu-J591, is designed to seek out prostate cancer
      cells and deliver a lethal dose of radiation to the areas of cancer, but not to normal areas.
      Some of the normal organs (liver, kidney and bone marrow) do receive some radiation dose that
      is within the acceptable limits.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2009</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of fractionated 177Lu-DOTA-J591 administered concurrently with three-weekly docetaxel for the treatment of patients with metastatic, castrate-resistant prostate cancer.</measure>
    <time_frame>4 weeks post last J591 dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the toxicity profile of concurrent docetaxel with fractionated 177Lu-DOTA-J591</measure>
    <time_frame>completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 20 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 25 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 30 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 35 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 40 mCi/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>10 mg per day starting on cycle 1, day 1</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Meticorten, Sterapred, Sterapred DS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic diagnosis of prostate adenocarcinoma.

          -  Patient must have progressive metastatic prostate cancer despite adequate medical or
             surgical castration therapy.

          -  Serum testosterone &lt; 50 mg/ml.

          -  Patients who have previously received docetaxel must meet BOTH of the the following
             criteria:

               -  reason for docetaxel discontinuation must NOT have been progression of disease
                  while receiving drug (i.e. progression of cancer must have been AFTER docetaxel
                  discontinuation) AND

               -  All docetaxel-related toxicities must have resolved to &lt; grade 1 (with the
                  exception of alopecia) and the pt must be eligible by other criteria

        Exclusion Criteria:

          -  Use of red blood cell or platelet transfusions within 4 weeks of treatment.

          -  Use of hematopoietic growth factors within 4 weeks of treatment.-Prior cytotoxic
             chemotherapy and/or radiation therapy within 4 weeks of treatment.

          -  Bone scan demonstrating confluent lesions involving both axial and appendicular
             skeleton (&quot;superscan&quot;).

          -  Prior radiation therapy encompassing &gt;25% of skeleton.Prior treatment with 89Strontium
             or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).

          -  Platelet count &lt;150,000/mm3.

          -  Absolute neutrophil count (ANC) &lt;2,000/mm3.

          -  Hematocrit &lt;30 percent or Hemoglobin &lt; 10 g/dL.

          -  Abnormal coagulation profile (PT or INR, PTT) &gt; 1.3 x upper limit of normal (unless on
             therapeutic anticoagulation).

          -  -Serum creatinine &gt;2.5 mg/dL.

          -  AST (SGOT) &gt;2.5x ULN.

          -  Bilirubin (total) &gt;1.5x ULN.

          -  Serum calcium &gt;11 mg/dL.

          -  Active serious infection.

          -  Active angina pectoris or New York Heart Association Class III-IV.

          -  ECOG Performance Status &gt;2.

          -  Life expectancy &lt;6 months.

          -  Deep vein thrombosis and/or pulmonary embolus within 1 month of study entry.

          -  Other serious illness(es) which might preclude completion of this study or interfere
             with determination of causality of any adverse effects experienced in this study.

          -  Prior anti-PSMA monoclonal antibody therapy with the exception of ProstaScint®.

          -  Prior investigational therapy within 6 weeks of treatment.

          -  Known history of HIV.

          -  Known history of myelodysplastic syndrome or leukemia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Tagawa, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>castrate-resistant prostate cancer</keyword>
  <keyword>CRPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

